Bsafe+ Home Download Template Menu 1 Menu 2 Menu 3 Menu 4 Menu 5

Creating Link

The "700,000-one shot" life-saving medicine dropped to more than 30,000, and it was officially launched!


Source: 21st Century Business Herald, Southern Plus, CCTV News, The Paper, Jiangxi Children's Hospital, Chengdu Daily·Jinguan News, etc.

On the first day of 2022, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)" was officially implemented.

According to the new version of the National Medical Insurance Drug List, a total of 74 drugs have been added to the list and 11 drugs have been removed from the list. In 2021, the total number of drugs in the National Medical Insurance Drug List is 2,860.

In addition, according to the 21st Century Business Herald, on the first day of the launch of the new version of the National Medical Insurance Drug List, nearly 20 spinal cord hospitals in 11 provinces and cities including Beijing, Shanghai, Guangdong, Zhejiang, Sichuan, Shandong, Hunan, Hubei, Fujian, Jiangxi, Henan, etc. Patients with SMA received Bojian’s "700,000 one shot" treatment of spinal muscular atrophy (SMA) drug Noxinassen sodium injection, which was the most concerned in this medical insurance negotiation. The price of the drug was reduced to Ten thousand yuan, greatly reducing the economic burden of the corresponding groups.

On the first day of the new year, many places open

Patient: "I feel so lucky"

On the first day of the New Year in 2022, the Department of Neurology, Jiangxi Children’s Hospital, gave Jiacheng (a pseudonym) a 2-year-old and 10-month-old child with SMA a treatment with Noxinagen sodium, giving SMA patients the best New Year gift, which is the target of SMA The first case in our province after the drug was included in the medical insurance, and also the first batch of patients in the country to benefit.

According to Nanfang+, at 9 am on January 1, in the treatment room of the Neurology Department of the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, 29-year-old patient Du lifted up his clothes and lay on his side on the bed, ready to receive a lumbar puncture. It is Nosina Sodium that is about to be injected into his body.

lumbar puncture

"Let your head closer to your chest, and arch your back a little more." Li Jing, the chief physician of the Department of Neurology of the First Affiliated Hospital of Sun Yat-sen University, gradually guided Mr. Du to adjust his posture. Mr. Du lay on the bed on his left side, bending his knees to hug him, exposing the lumbar spine.

"Keep the back and the bed as vertical as possible. When the needle is inserted, it is slightly inclined and slowly upward..." Professor Zhang Cheng, the chief physician and professor of neurosurgery of Zhongshan First Hospital, came to the scene to give guidance.

On the other side, doctor Xu Ruikai is ready to go in the hospital pharmacy. He has an incubator in his hand, which is cryopreserved sodium injection of Noxine. "You can get the medicine." It didn't take long before he received the order to deliver the medicine.

The tip of the needle entered the body, and Mr. Du clenched his fist. "Relax a little, breathe normally, don't strain your stomach." The medical staff continued to guide patiently.

After the lumbar puncture was completed, the attending physician He Ruojie took the injection from the cold incubator, held it in the palm of his hand, and reheated the injection to about 25 degrees Celsius. After 2 minutes, the temperature measuring gun showed that the temperature of the injection was appropriate.

Li Jing and He Ruojie cooperated and used a syringe to suck out the 5 ml of Noxine Sodium Injection from the vial. "You need to be very careful in this step. Every drop of medicine is precious. Try to suck it into the needle as much as possible."

After inhaling all of them, Li Jing slowly injected the injection into Mr. Du's body to complete the treatment.

" I can use this medicine on the first day of the new year, and I feel lucky! " Mr. Du is full of longing for the future, "I hope I can get back to health in the future, go to work, and live a normal life. I also hope that more patients, especially children, Can restore health."

The doctor injects the patient

Nosinasana Injection

At the same time, the reporter came to the Binjiang Campus of the Children’s Hospital Affiliated to Zhejiang University School of Medicine (hereinafter referred to as "Zhejiang University Children’s Hospital") on the morning of the 1st. Xin is waiting for the injection of Nosina Sodium.

At 10:36 am, Xinxin was taken into the injection room; at 10:48, the doctor team opened the door and the whole process ended.

Mao Shanshan, chief physician of the Department of Neurology, Children's Hospital Affiliated to Zhejiang University School of Medicine, leader of the Multi-scientific Diagnosis and Treatment Team for Spinal Muscular Atrophy (SMA-MDT), and also the leader of the SMA diagnosis and treatment expert group in Zhejiang Province, introduced to reporters, Xin Xin He was diagnosed with SMA Type II at the age of 1 year and 9 months. He has been under the management and rehabilitation of the multi-scientific diagnosis and treatment team before.

"Every small group should not be abandoned"

"I hope the company will make a more sincere offer... Every small group should not be given up."

In the past, the high price of Noxinagen Sodium Injection made it difficult for many patients, including Mr. Du and Xinxin.

But it's different now. At the end of 2021, a video of medical insurance negotiators and business representatives starting price negotiations on rare disease drugs received attention. The video Chinese medical insurance negotiator "killed" the price of the drug from the market price of 700,000 yuan to about 30,000 yuan, which caused netizens to like it.

In this year’s negotiations, the negotiation of drugs for the treatment of rare disease spinal muscular atrophy lasted for one and a half hours.

Reviewing the whole process can be described as extremely difficult. In the first round of quotations, the price given by the company was 53680 per bottle. Zhang Jinni, the negotiator of the National Medical Insurance Administration, replied: "I hope that companies will offer more sincere quotations, and every small group should not be given up."

And gave a quite "tempting" condition-"If this drug can enter the medical insurance catalog, with China's population base and the Chinese government's determination to serve patients, it will be difficult to find such a market."

After the business representatives left the meeting to discuss. The offer price dropped to 48,000 yuan per bottle.

Zhang Jinni said frankly that China’s medical insurance fund is actually a very difficult year, including the early stage of the new coronary pneumonia. The medical insurance fund’s levy and mitigation may also enjoy corresponding concessions. Vaccine costs actually account for a very, very large expenditure of the medical insurance fund.

"So we still have the courage to carry out medical insurance negotiations with the National Medical Insurance Bureau this year, and we have indeed experienced the great determination of the people's health first ."

Zhang Jinni's words caused the business representatives to leave the meeting again to discuss.

This time they lowered the price to 45,800 yuan.

And Zhang Jinni’s answer was: “It’s very difficult. I hope the company will work harder.”

After the negotiating company left the meeting for the third time, the price of 42,800 was brought back.

This time Zhang Jinni replied: "I believe the company feels very painful, but there is still a certain distance before we can talk further ."

The negotiating company has gone through the fourth and fifth time to negotiate, and the price has dropped to 37,800 per bottle. But this obviously has not reached the ideal price of the Medical Insurance Bureau.

Zhang Jinni smiled and said: "We, as Party A, are so humble at the negotiating table . It's really difficult."

But the negotiating team cannot give in to the bottom line of the price.

"The adjustment space is 0" "It's really hard, I think my tears were almost falling off just now."

Subsequently, after collective deliberations by the negotiating team, Zhang Jinni gave an offer of 33,000.

The business representatives left the meeting for the eighth time and finally confirmed the new quotation:

"Is this the final quotation you confirmed?"

"confirm."

"Okay, deal."

After one and a half hours of long negotiations, business representatives left the meeting for eight times. The transaction price of each bottle of medicine was more than 20,000 yuan less than the original price.

The drug whose price has been knocked down is Noxinagen Sodium Injection. This is the first time that a rare disease drug has been included in the medical insurance drug list and will be officially implemented on January 1, 2022 .

This means that more children with SMA can afford the medicine, and it greatly reduces the financial burden of the patient's family. The family members of the patient cried with joy when they heard the news!

Xing Huanping, Executive Director of Meier's SMA Care Center, said: "We have witnessed that the patient population has gone from no medicines, to hope of treatment, and to enjoy the medical insurance policy today. The burden on families has been greatly reduced. This is the most received by SMA patients and families across the country. Good New Year gift."

Why is Nosina Sodium priced so expensive?

SMA, or spinal muscular atrophy, is an autosomal recessive genetic disease caused by genetic defects, and it is also one of the most common genetic diseases that cause infant death.

Professor Huang Shaoping, chief expert of the Children’s SMA Diagnosis and Treatment Center of the Second Affiliated Hospital of Xi’an Jiaotong University, and head of the pediatric treatment team, introduced that SMA is a rare disease that causes muscle weakness and muscle atrophy due to the degeneration of the anterior horn of the spinal cord. The rate is about 1 in 10,000 .

It is understood that in May 2018, spinal muscular atrophy was included in the "First List of Rare Diseases" jointly formulated by the National Health Commission and other departments, and it is the second-ranked neuromuscular rare disease.

Jin Ruifeng, director of the Pediatric Neurology Department of Qilu Children's Hospital of Shandong University, further introduced that there is one SMA recessive gene carrier in about 40-50 ordinary people. As an autosomal recessive genetic neuromuscular disease, according to genetic probability, if two carriers combine, there is a one-quarter chance of giving birth to a child with SMA in each pregnancy . However, there is a high probability that children with onset of the disease in infancy will not live to 2 years old. Therefore, SMA is also known as the "top genetic disease killer" for infants under 2 years of age.

The Noxinassen Sodium Injection developed by Biojian Company is the world's first disease-modifying treatment for the cause of SMA . In December 2016, Noxinassen Sodium Injection was approved in the United States. In 2018, Noxinassen Sodium Injection was included in China's "List of the First Batch of New Drugs Urgently Needed for Clinical Use", and was approved for listing in China in February 2019. At the beginning of the domestic approval for listing, the price per unit of Nosinagenic Sodium was 699,700 yuan, which has now been reduced to 550,000 yuan, a unified national price .

It is reported that the treatment of Noxinagen sodium includes two parts: loading dose and maintenance dose. It needs to be injected intrathecally on the first day, 14th day, 28th day, and 63rd day, and once every 4 months thereafter, for lifelong medication . According to the latest SMA patient assistance program, patients can enjoy the loading dose "1+5" assistance program, that is, buy 1 bottle and get 5 bottles, and the maintenance dose assistance program thereafter will be "1+2". This means that the patient's annual treatment cost is 550,000 yuan.

In the United States, the price of Noxinagen Sodium Injection is US$125,000 per injection. It requires 6 injections in the first year, and the treatment cost is about US$750,000. The cost in the second year is reduced by half to US$375,000. Donna Sullivan, the chief pharmacist of the Washington State Department of Health Care, has publicly expressed dissatisfaction, saying that although the drug brings some hope to SMA patients, the huge cost will put tremendous pressure on Washington State’s Medicaid budget, which may lead to Legislators had to cut other optional Medicaid services.

Why is Nosina Sodium priced so expensive?

In fact, unlike ordinary drugs, the number of rare disease patients is small, and there are few companies willing to invest in research and development. The progress of drug research and development is slow, and in order to recover the cost of research and development, the company's pricing is naturally relatively high .

In addition, during the development process, the failure rate of rare disease drugs is significantly higher . According to the report jointly issued by the global biotechnology industry organization BIO, Informa Pharma Intelligence and QLS, in the past ten years (2011-2020), 9704 drug clinical development projects, from phase 1 clinical trials to obtaining US FDA approval for listing, required The average time is 10.5 years. And rare disease drugs from clinical to approved, it takes four years longer than other drugs. At the same time, clinical trials of rare disease drugs also have the characteristics of small sample size, large heterogeneity, and difficulty in recruiting, making the failure rate of screening and randomization at any stage of the clinical trial significantly higher.

In response to the dispute over drug pricing, Bojian spokesperson Matt Fearer once said that this has been fully considered. " The pricing strategy of Noxinagen Sodium is no different from other rare disease orphan drugs. This price is mainly based on the full evaluation of the pre-investment and clinical value of the drug, as well as Biogen's need to continuously invest in other innovative drug research projects. "

Jin Enlin, general manager and head of strategy and investment of JD Health and Medicine Department, said: “Rare diseases are first of all a medical problem, but also an economic problem. For example, most rare disease patients are still without medicines. This problem is a market failure. How to break market failures, enable companies to produce, develop and provide medicines for a small number of patients, and enable these companies to profit and maintain sustainable development is a unique challenge in the field of rare diseases."

The rate of price cuts in this medical insurance negotiation reached the highest ever

94 drugs successfully negotiated

The scope of the adjustment of the National Medical Insurance Drug List in 2021 includes drugs newly marketed or modified in the label in the past 5 years, national essential drugs, and drugs used for the treatment of new coronary pneumonia. The newly-incorporated drugs accurately complement the medication needs of tumors, chronic diseases, anti-infections, rare diseases, women and children, and involve a total of 21 clinical groups. Patients benefit from a wide range of drugs. The accessibility and fairness of medications for the masses has been further improved.

After the adjustment, the total number of drugs in the National Medical Insurance Drug List is 2,860, of which 1,486 are Western medicines and 1,374 are Chinese patent medicines. There are still 892 kinds of Chinese herbal medicines. During the adjustment, the National Medical Security Administration has always adhered to the functional positioning of "guarantee basic", regarded fund affordability as the "bottom line" that must be adhered to, and strived to meet the basic drug needs of the majority of insured persons.

In terms of price reduction, 94 negotiations were successful, with an overall success rate of 80.34%. Among them, the 85 exclusive drugs outside the catalogue reached 67, with a success rate of 78.82% and an average price reduction of 61.71%. Regardless of the success rate or the decline, it has also reached the highest ever.

According to the 21st Century Business Herald, BeiGene's BTK inhibitor Baiyueze (Zebutinib) has successfully added the indications for Wah's macroglobulinemia (WM) into the 2021 version of the National Medical Insurance List after the negotiation of the 2021 medical insurance catalogue. Reduce the financial burden of patients. Currently, Baiyueze has three indications included in the medical insurance catalog, covering mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.

This time, Baiyueze cut the price by 14% after the 44% price cut in the medical insurance negotiations in 2020. The latest medical insurance implementation price after the second price cut is 5440 yuan/box, and the monthly treatment cost is 10,200 yuan before reimbursement. If calculated according to the national average 70% medical insurance reimbursement ratio, the monthly treatment fee after reimbursement of Baiyueze will be reduced to about 3060 yuan. After the price cut, Baiyueze became the product with the lowest monthly treatment cost among similar BTK inhibitors.

The controversial Green Valley Pharmaceutical's Alzheimer's disease drug Phase IX 1 (mannite sodium) has been included in the medical insurance catalog with a 66% price reduction, and the latest price is 7.05 yuan/150mg.

With the continuous deepening of medical insurance reform, the time for the implementation of medical insurance policies has also been shortened year by year. It took less than a month from the announcement of the results of the negotiations to the patients receiving treatment under the medical insurance reimbursement policy. It can be seen that, while ensuring the effective implementation of policies, it has become a trend to truly open up the "last mile" of medical insurance medication for patients.

IQVIA also believes that, judging from the results of this medical insurance negotiation, policy changes will guide the innovation and upgrading of the pharmaceutical industry, and the commercial success of pharmaceuticals in the future will rely more on innovation. On the one hand, policy changes have brought advancement in the time of listing and medical insurance access, and the key points of pharmaceutical commercial success have also been advanced; on the other hand, centralized and large-scale procurement has shortened the life cycle of drugs, and companies need to innovate and win with innovation; at the same time, The commercial success of pharmaceuticals will gradually transform from relying on sales to relying on evidence production, value positioning and value delivery; in addition, measures such as dynamic adjustment of the medical insurance catalog and centralized procurement will optimize the use of funds while also forcing the pharmaceutical industry to innovate and upgrade.

Search This Blog

The "700,000-one shot" life-saving medicine dropped to more than 30,000, and it was officially launched!

Source: 21st Century Business Herald, Southern Plus, CCTV News, The Paper, Jiangxi Children's Hospital, Chengdu Daily·Jinguan News, etc.

On the first day of 2022, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)" was officially implemented.

According to the new version of the National Medical Insurance Drug List, a total of 74 drugs have been added to the list and 11 drugs have been removed from the list. In 2021, the total number of drugs in the National Medical Insurance Drug List is 2,860.

In addition, according to the 21st Century Business Herald, on the first day of the launch of the new version of the National Medical Insurance Drug List, nearly 20 spinal cord hospitals in 11 provinces and cities including Beijing, Shanghai, Guangdong, Zhejiang, Sichuan, Shandong, Hunan, Hubei, Fujian, Jiangxi, Henan, etc. Patients with SMA received Bojian’s "700,000 one shot" treatment of spinal muscular atrophy (SMA) drug Noxinassen sodium injection, which was the most concerned in this medical insurance negotiation. The price of the drug was reduced to Ten thousand yuan, greatly reducing the economic burden of the corresponding groups.

On the first day of the new year, many places open

Patient: "I feel so lucky"

On the first day of the New Year in 2022, the Department of Neurology, Jiangxi Children’s Hospital, gave Jiacheng (a pseudonym) a 2-year-old and 10-month-old child with SMA a treatment with Noxinagen sodium, giving SMA patients the best New Year gift, which is the target of SMA The first case in our province after the drug was included in the medical insurance, and also the first batch of patients in the country to benefit.

According to Nanfang+, at 9 am on January 1, in the treatment room of the Neurology Department of the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, 29-year-old patient Du lifted up his clothes and lay on his side on the bed, ready to receive a lumbar puncture. It is Nosina Sodium that is about to be injected into his body.

lumbar puncture

"Let your head closer to your chest, and arch your back a little more." Li Jing, the chief physician of the Department of Neurology of the First Affiliated Hospital of Sun Yat-sen University, gradually guided Mr. Du to adjust his posture. Mr. Du lay on the bed on his left side, bending his knees to hug him, exposing the lumbar spine.

"Keep the back and the bed as vertical as possible. When the needle is inserted, it is slightly inclined and slowly upward..." Professor Zhang Cheng, the chief physician and professor of neurosurgery of Zhongshan First Hospital, came to the scene to give guidance.

On the other side, doctor Xu Ruikai is ready to go in the hospital pharmacy. He has an incubator in his hand, which is cryopreserved sodium injection of Noxine. "You can get the medicine." It didn't take long before he received the order to deliver the medicine.

The tip of the needle entered the body, and Mr. Du clenched his fist. "Relax a little, breathe normally, don't strain your stomach." The medical staff continued to guide patiently.

After the lumbar puncture was completed, the attending physician He Ruojie took the injection from the cold incubator, held it in the palm of his hand, and reheated the injection to about 25 degrees Celsius. After 2 minutes, the temperature measuring gun showed that the temperature of the injection was appropriate.

Li Jing and He Ruojie cooperated and used a syringe to suck out the 5 ml of Noxine Sodium Injection from the vial. "You need to be very careful in this step. Every drop of medicine is precious. Try to suck it into the needle as much as possible."

After inhaling all of them, Li Jing slowly injected the injection into Mr. Du's body to complete the treatment.

" I can use this medicine on the first day of the new year, and I feel lucky! " Mr. Du is full of longing for the future, "I hope I can get back to health in the future, go to work, and live a normal life. I also hope that more patients, especially children, Can restore health."

The doctor injects the patient

Nosinasana Injection

At the same time, the reporter came to the Binjiang Campus of the Children’s Hospital Affiliated to Zhejiang University School of Medicine (hereinafter referred to as "Zhejiang University Children’s Hospital") on the morning of the 1st. Xin is waiting for the injection of Nosina Sodium.

At 10:36 am, Xinxin was taken into the injection room; at 10:48, the doctor team opened the door and the whole process ended.

Mao Shanshan, chief physician of the Department of Neurology, Children's Hospital Affiliated to Zhejiang University School of Medicine, leader of the Multi-scientific Diagnosis and Treatment Team for Spinal Muscular Atrophy (SMA-MDT), and also the leader of the SMA diagnosis and treatment expert group in Zhejiang Province, introduced to reporters, Xin Xin He was diagnosed with SMA Type II at the age of 1 year and 9 months. He has been under the management and rehabilitation of the multi-scientific diagnosis and treatment team before.

"Every small group should not be abandoned"

"I hope the company will make a more sincere offer... Every small group should not be given up."

In the past, the high price of Noxinagen Sodium Injection made it difficult for many patients, including Mr. Du and Xinxin.

But it's different now. At the end of 2021, a video of medical insurance negotiators and business representatives starting price negotiations on rare disease drugs received attention. The video Chinese medical insurance negotiator "killed" the price of the drug from the market price of 700,000 yuan to about 30,000 yuan, which caused netizens to like it.

In this year’s negotiations, the negotiation of drugs for the treatment of rare disease spinal muscular atrophy lasted for one and a half hours.

Reviewing the whole process can be described as extremely difficult. In the first round of quotations, the price given by the company was 53680 per bottle. Zhang Jinni, the negotiator of the National Medical Insurance Administration, replied: "I hope that companies will offer more sincere quotations, and every small group should not be given up."

And gave a quite "tempting" condition-"If this drug can enter the medical insurance catalog, with China's population base and the Chinese government's determination to serve patients, it will be difficult to find such a market."

After the business representatives left the meeting to discuss. The offer price dropped to 48,000 yuan per bottle.

Zhang Jinni said frankly that China’s medical insurance fund is actually a very difficult year, including the early stage of the new coronary pneumonia. The medical insurance fund’s levy and mitigation may also enjoy corresponding concessions. Vaccine costs actually account for a very, very large expenditure of the medical insurance fund.

"So we still have the courage to carry out medical insurance negotiations with the National Medical Insurance Bureau this year, and we have indeed experienced the great determination of the people's health first ."

Zhang Jinni's words caused the business representatives to leave the meeting again to discuss.

This time they lowered the price to 45,800 yuan.

And Zhang Jinni’s answer was: “It’s very difficult. I hope the company will work harder.”

After the negotiating company left the meeting for the third time, the price of 42,800 was brought back.

This time Zhang Jinni replied: "I believe the company feels very painful, but there is still a certain distance before we can talk further ."

The negotiating company has gone through the fourth and fifth time to negotiate, and the price has dropped to 37,800 per bottle. But this obviously has not reached the ideal price of the Medical Insurance Bureau.

Zhang Jinni smiled and said: "We, as Party A, are so humble at the negotiating table . It's really difficult."

But the negotiating team cannot give in to the bottom line of the price.

"The adjustment space is 0" "It's really hard, I think my tears were almost falling off just now."

Subsequently, after collective deliberations by the negotiating team, Zhang Jinni gave an offer of 33,000.

The business representatives left the meeting for the eighth time and finally confirmed the new quotation:

"Is this the final quotation you confirmed?"

"confirm."

"Okay, deal."

After one and a half hours of long negotiations, business representatives left the meeting for eight times. The transaction price of each bottle of medicine was more than 20,000 yuan less than the original price.

The drug whose price has been knocked down is Noxinagen Sodium Injection. This is the first time that a rare disease drug has been included in the medical insurance drug list and will be officially implemented on January 1, 2022 .

This means that more children with SMA can afford the medicine, and it greatly reduces the financial burden of the patient's family. The family members of the patient cried with joy when they heard the news!

Xing Huanping, Executive Director of Meier's SMA Care Center, said: "We have witnessed that the patient population has gone from no medicines, to hope of treatment, and to enjoy the medical insurance policy today. The burden on families has been greatly reduced. This is the most received by SMA patients and families across the country. Good New Year gift."

Why is Nosina Sodium priced so expensive?

SMA, or spinal muscular atrophy, is an autosomal recessive genetic disease caused by genetic defects, and it is also one of the most common genetic diseases that cause infant death.

Professor Huang Shaoping, chief expert of the Children’s SMA Diagnosis and Treatment Center of the Second Affiliated Hospital of Xi’an Jiaotong University, and head of the pediatric treatment team, introduced that SMA is a rare disease that causes muscle weakness and muscle atrophy due to the degeneration of the anterior horn of the spinal cord. The rate is about 1 in 10,000 .

It is understood that in May 2018, spinal muscular atrophy was included in the "First List of Rare Diseases" jointly formulated by the National Health Commission and other departments, and it is the second-ranked neuromuscular rare disease.

Jin Ruifeng, director of the Pediatric Neurology Department of Qilu Children's Hospital of Shandong University, further introduced that there is one SMA recessive gene carrier in about 40-50 ordinary people. As an autosomal recessive genetic neuromuscular disease, according to genetic probability, if two carriers combine, there is a one-quarter chance of giving birth to a child with SMA in each pregnancy . However, there is a high probability that children with onset of the disease in infancy will not live to 2 years old. Therefore, SMA is also known as the "top genetic disease killer" for infants under 2 years of age.

The Noxinassen Sodium Injection developed by Biojian Company is the world's first disease-modifying treatment for the cause of SMA . In December 2016, Noxinassen Sodium Injection was approved in the United States. In 2018, Noxinassen Sodium Injection was included in China's "List of the First Batch of New Drugs Urgently Needed for Clinical Use", and was approved for listing in China in February 2019. At the beginning of the domestic approval for listing, the price per unit of Nosinagenic Sodium was 699,700 yuan, which has now been reduced to 550,000 yuan, a unified national price .

It is reported that the treatment of Noxinagen sodium includes two parts: loading dose and maintenance dose. It needs to be injected intrathecally on the first day, 14th day, 28th day, and 63rd day, and once every 4 months thereafter, for lifelong medication . According to the latest SMA patient assistance program, patients can enjoy the loading dose "1+5" assistance program, that is, buy 1 bottle and get 5 bottles, and the maintenance dose assistance program thereafter will be "1+2". This means that the patient's annual treatment cost is 550,000 yuan.

In the United States, the price of Noxinagen Sodium Injection is US$125,000 per injection. It requires 6 injections in the first year, and the treatment cost is about US$750,000. The cost in the second year is reduced by half to US$375,000. Donna Sullivan, the chief pharmacist of the Washington State Department of Health Care, has publicly expressed dissatisfaction, saying that although the drug brings some hope to SMA patients, the huge cost will put tremendous pressure on Washington State’s Medicaid budget, which may lead to Legislators had to cut other optional Medicaid services.

Why is Nosina Sodium priced so expensive?

In fact, unlike ordinary drugs, the number of rare disease patients is small, and there are few companies willing to invest in research and development. The progress of drug research and development is slow, and in order to recover the cost of research and development, the company's pricing is naturally relatively high .

In addition, during the development process, the failure rate of rare disease drugs is significantly higher . According to the report jointly issued by the global biotechnology industry organization BIO, Informa Pharma Intelligence and QLS, in the past ten years (2011-2020), 9704 drug clinical development projects, from phase 1 clinical trials to obtaining US FDA approval for listing, required The average time is 10.5 years. And rare disease drugs from clinical to approved, it takes four years longer than other drugs. At the same time, clinical trials of rare disease drugs also have the characteristics of small sample size, large heterogeneity, and difficulty in recruiting, making the failure rate of screening and randomization at any stage of the clinical trial significantly higher.

In response to the dispute over drug pricing, Bojian spokesperson Matt Fearer once said that this has been fully considered. " The pricing strategy of Noxinagen Sodium is no different from other rare disease orphan drugs. This price is mainly based on the full evaluation of the pre-investment and clinical value of the drug, as well as Biogen's need to continuously invest in other innovative drug research projects. "

Jin Enlin, general manager and head of strategy and investment of JD Health and Medicine Department, said: “Rare diseases are first of all a medical problem, but also an economic problem. For example, most rare disease patients are still without medicines. This problem is a market failure. How to break market failures, enable companies to produce, develop and provide medicines for a small number of patients, and enable these companies to profit and maintain sustainable development is a unique challenge in the field of rare diseases."

The rate of price cuts in this medical insurance negotiation reached the highest ever

94 drugs successfully negotiated

The scope of the adjustment of the National Medical Insurance Drug List in 2021 includes drugs newly marketed or modified in the label in the past 5 years, national essential drugs, and drugs used for the treatment of new coronary pneumonia. The newly-incorporated drugs accurately complement the medication needs of tumors, chronic diseases, anti-infections, rare diseases, women and children, and involve a total of 21 clinical groups. Patients benefit from a wide range of drugs. The accessibility and fairness of medications for the masses has been further improved.

After the adjustment, the total number of drugs in the National Medical Insurance Drug List is 2,860, of which 1,486 are Western medicines and 1,374 are Chinese patent medicines. There are still 892 kinds of Chinese herbal medicines. During the adjustment, the National Medical Security Administration has always adhered to the functional positioning of "guarantee basic", regarded fund affordability as the "bottom line" that must be adhered to, and strived to meet the basic drug needs of the majority of insured persons.

In terms of price reduction, 94 negotiations were successful, with an overall success rate of 80.34%. Among them, the 85 exclusive drugs outside the catalogue reached 67, with a success rate of 78.82% and an average price reduction of 61.71%. Regardless of the success rate or the decline, it has also reached the highest ever.

According to the 21st Century Business Herald, BeiGene's BTK inhibitor Baiyueze (Zebutinib) has successfully added the indications for Wah's macroglobulinemia (WM) into the 2021 version of the National Medical Insurance List after the negotiation of the 2021 medical insurance catalogue. Reduce the financial burden of patients. Currently, Baiyueze has three indications included in the medical insurance catalog, covering mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.

This time, Baiyueze cut the price by 14% after the 44% price cut in the medical insurance negotiations in 2020. The latest medical insurance implementation price after the second price cut is 5440 yuan/box, and the monthly treatment cost is 10,200 yuan before reimbursement. If calculated according to the national average 70% medical insurance reimbursement ratio, the monthly treatment fee after reimbursement of Baiyueze will be reduced to about 3060 yuan. After the price cut, Baiyueze became the product with the lowest monthly treatment cost among similar BTK inhibitors.

The controversial Green Valley Pharmaceutical's Alzheimer's disease drug Phase IX 1 (mannite sodium) has been included in the medical insurance catalog with a 66% price reduction, and the latest price is 7.05 yuan/150mg.

With the continuous deepening of medical insurance reform, the time for the implementation of medical insurance policies has also been shortened year by year. It took less than a month from the announcement of the results of the negotiations to the patients receiving treatment under the medical insurance reimbursement policy. It can be seen that, while ensuring the effective implementation of policies, it has become a trend to truly open up the "last mile" of medical insurance medication for patients.

IQVIA also believes that, judging from the results of this medical insurance negotiation, policy changes will guide the innovation and upgrading of the pharmaceutical industry, and the commercial success of pharmaceuticals in the future will rely more on innovation. On the one hand, policy changes have brought advancement in the time of listing and medical insurance access, and the key points of pharmaceutical commercial success have also been advanced; on the other hand, centralized and large-scale procurement has shortened the life cycle of drugs, and companies need to innovate and win with innovation; at the same time, The commercial success of pharmaceuticals will gradually transform from relying on sales to relying on evidence production, value positioning and value delivery; in addition, measures such as dynamic adjustment of the medical insurance catalog and centralized procurement will optimize the use of funds while also forcing the pharmaceutical industry to innovate and upgrade.

Comments


Ad Blocker Detected

Please turn off your adBlock because only ads make us excited, Thank you !!!